Phuong N.U Nguyen

Ms. Phuong N.U Nguyen

University of British Columbia, Vancouver, British Columbia, Canada
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MGMeiyun Guo
Meiyun Guo
JRJenna Rever
Jenna Rever
PNPhuong N.U Nguyen
Phuong N.U Nguyen
NANeha Manjari Akella
Neha Manjari Akella
GRGregor Reid
Gregor Reid
CMChristopher Maxwell
Christopher Maxwell
Acute lymphoblastic leukemia (ALL) is the most common form of cancer in children, with most cases arising from fetal B cell precursor, termed B-ALL. Here, we use immunofluorescence analysis of B-ALL cells to identify centrosome amplification events that require the centrosome clustering pathway to successfully complete mitosis. Our data reveals that primary human B-ALL cells and immortal B-ALL cell lines from both human and mouse sources show defective bipolar spindle formation, abnormal mitotic progression, and cell death following treatment with centrosome clustering inhibitors (CCI). We demonstrate that CCI-refractory B-ALL cells exhibit markers for increased genomic instability, including DNA damage and micronuclei, as well as activation of the cyclic GMP–AMP synthase (cGAS)-nuclear factor kappa B (NF-κB) signalling pathway. Our analysis of cGAS knock-down B-ALL clones implicates cGAS in the sensitivity of B-ALL cells to CCI treatment. Due to its integral function and specificity to cancer cells, the centrosome clustering pathway presents a powerful molecular target for cancer treatment while mitigating the risk to healthy cells.

25 September 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
KCKai Cao
Kai Cao
RLRui Li
Rui Li
MSMartin Stražar
Martin Stražar
EBEric M. Brown
Eric M. Brown
PNPhuong N.U Nguyen
Phuong N.U Nguyen
RXRamnik J. Xavier
Ramnik J. Xavier
Interactions between T cell receptors (TCRs), peptides, and human leukocyte antigens (HLAs) underlie antigen-specific T cell immunity. Despite substantial advances in prediction methods, accurate modeling of coupled TCR–peptide–HLA recognition remains underdeveloped, limiting applications such as TCR and neoepitope prioritization in cancer and antigen identification in autoimmunity. Here we present StriMap, a unified framework for predicting TCR–peptide–HLA interactions by integrating physicochemical, sequence-context, and structural features at recognition interfaces. StriMap achieves state-of-the-art performance with improved generalizability and enables applications in cancer and autoimmunity. As a case study, we screened 13 million peptides from 43,241 bacterial proteins and identified candidate molecular mimics that were experimentally validated to activate T cells expressing an ankylosing spondylitis (AS)-associated TCR. A top validated peptide was enriched in patients with inflammatory bowel disease (IBD), suggesting potential shared microbial triggers. Overall, StriMap provides a framework for rational immunotherapy design and dissecting antigenic drivers of autoimmunity.